

~~14~~ 13. A peptide comprising or consisting of the sequence YMVH  
or MVHW or VHWK and having at least 70% homology with part or all  
of the sequence

~~AEPHRWSSY~~YMVHWK.

~~15~~ 14. A mixture of the peptide of claim ~~12~~ or claim ~~13~~ with  
another peptide having at least 4 amino acid residues and having at  
least 70% homology with the  $\beta$ -amyloid precursor sequence

~~DAEFRHDSGYEVHHQK.~~

~~16~~ 15. A probe consisting of the peptide of claim ~~12~~ or claim ~~13~~

~~17~~ 16. labelled with a signal moiety, or immobilised on a support.

~~17~~ 16. A probe consisting of the peptide of claim ~~14~~, labelled  
with a signal moiety, or immobilised on a support.

~~18~~ 17. A compound which competes with the peptide of claim ~~12~~ or  
claim ~~13~~ for binding to a receptor therefor and which thereby  
inhibits the biological activity of the said peptide.

~~18~~ 18. A compound as claimed in claim ~~17~~, wherein the biological  
activity is modulating a calcium-channel-opening activity.

~~19~~ 19. A compound as claimed in claim ~~17~~, which is capable of  
crossing the blood-brain barrier.

~~20~~ 20. An antibody to the peptide of claim ~~16~~ or claim ~~13~~.

~~21~~ 21. An antibody as claimed in claim ~~20~~ which is of the IgG  
class.

~~22~~ 22. An antibody fragment or chimeric or humanised antibody  
comprising variable regions of the antibody of claim ~~20~~.

*b7b*

~~24~~ 23. A method of treating a patient suffering from a disorder of the central nervous system or stroke or cancer, which method comprises administering to the patient a compound according to claim ~~19~~.

*1 concus*

~~25~~ 24. A method of treating a patient suffering from a disorder of the central nervous system or stroke or cancer, which method comprises administering to the patient an antibody according to claim ~~20~~.

~~26~~ 25. A method of controlling cytoplasmic calcium ion concentration *in vivo*, which method comprises administering a compound according to claim ~~18~~.

~~27~~ 26. A method of controlling cytoplasmic calcium ion concentration *in vivo*, which method comprises administering an antibody according to claim ~~20~~.

~~28~~ 27. A peptide as claimed in claim ~~12~~ or claim ~~13~~, which peptide contains no more than about 14 amino acid residues.

*H2 2nd* ~~29~~ 28. A peptide as claimed in claim ~~12~~ or claim ~~13~~, which peptide does not form part of a larger protein having homology with the AChE molecule.

*SuO* ~~30~~ 29. A peptide as claimed in claim ~~12~~ or claim ~~13~~, which peptide is a fragment of the AChE molecule.

*E6* ~~31~~ 30. A peptide as claimed in claim ~~12~~ or claim ~~13~~, which peptide has been chemically synthesised. --